Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia
- 15 September 2019
- book chapter
- Published by Springer Nature
- Vol. 2032, 311-321
Abstract
Flow-cytometric demonstration of the typical chronic lymphocytic leukemia (CLL) immunophenotype is vital for diagnosis. CLL has a characteristic immunophenotype, expressing CD5, CD19, dim CD20, dim CD22, CD23, bright CD43, dim CD45, dim to negative CD79b, dim CD81, CD200, and dim monoclonal surface immunoglobulin. This characteristic immunophenotype allows a definitive diagnosis and the ruling out of another leukemia or lymphoma. Flow cytometry also provides important prognostic information and accurate assessment of response to therapy. Here we describe optimal specimen collection, red cell lysis, appropriate panel, cell staining, acquisition on a flow cytometer, and analysis for CLL specimens.Keywords
This publication has 20 references indexed in Scilit:
- Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLLLeukemia, 2012
- Diagnostic Usefulness and Prognostic Impact of CD200 Expression in Lymphoid Malignancies and Plasma Cell MyelomaAmerican Journal of Clinical Pathology, 2012
- Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemiaCytometry Part B: Clinical Cytometry, 2008
- Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemiaBlood, 2008
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Diagnostic criteria for monoclonal B‐cell lymphocytosisBritish Journal of Haematology, 2005
- Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged SurvivalJournal of Clinical Oncology, 2005
- Phenotypic Heterogeneity of B Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaAmerican Journal of Clinical Pathology, 2003
- CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B‐cell neoplasmsCytometry, 2002
- CD38 expression is an important prognostic marker in chronic lymphocytic leukaemiaLeukemia, 2002